SDS Optic SA

SDS Optic SA exhibits a weak capital structure and liquidity position, with a current ratio of 0.94, indicating that its current liabilities exceed its current assets. The company has no long-term debt, but its operating cash flow of -2.71 million PLN and free cash flow of -2.39 million PLN suggest significant cash outflows from operations. The debt-to-equity ratio is 0.0, reflecting no leverage in its capital structure.

Profitability metrics are deeply negative, with a return on equity of -98.61% and a return on assets of -15.48%, both far below the typical thresholds for a viable business. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.

The company's revenue is reported as 0.0 PLN, and its gross profit is negative at -121,490 PLN, suggesting that it is not currently generating revenue from its operations and is incurring significant production or service delivery costs. The operating income of -2.49 million PLN and net income of -2.49 million PLN further underscore the company's unprofitable operations.

There is no disclosed segment or geographic revenue breakdown in the available data, making it difficult to assess the company's exposure to different markets or product lines. The absence of revenue concentration data limits the ability to evaluate the company's diversification and risk profile.

The company's growth trajectory is not evident from the data, as there is no revenue history provided to assess trends over time. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and unprofitable operations suggest a high operational risk.

There are no recent events, filings, or transcripts provided in the available data to inform the company's current strategic direction or operational developments.

Operating income improved by 45.5% year-over-year, signaling a meaningful reduction in operational losses for the company.

Free cash flow improved by 46.8% year-over-year, indicating better cash generation capabilities despite ongoing negative balances.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio of 0.0 and eliminating interest obligations.

Cash conversion metrics rank above the median for the biotechnology cohort, suggesting relatively efficient cash management practices.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for current shareholders.

The company reported a net loss of 3.02 billion PLN, continuing a pattern of substantial profitability challenges.

Credit risk is flagged as high, indicating potential difficulties in meeting financial obligations or securing favorable financing terms.

Free cash flow remains deeply negative at -2.61 billion PLN, requiring continuous external capital to sustain operations.